Atorlip 20
Atorlip 20 Price range: $ 74,00 through $ 542,00
Back to products
Atrovent
Atrovent Price range: $ 22,00 through $ 65,00

Atorlip 5

Price range: $ 43,00 through $ 157,00

Atorlip 5 is an effective medication designed to help manage and lower high cholesterol levels in the blood. It belongs to the class of drugs known as statins, which work by reducing the production of LDL or “bad” cholesterol in the liver. Regular use of this treatment helps balance lipid profiles by decreasing triglycerides and increasing beneficial HDL cholesterol. By maintaining healthy cholesterol levels, Atorlip 5 plays a crucial role in reducing the risk of heart attacks and strokes. This medication is typically used alongside a heart-healthy diet and regular exercise to support long-term cardiovascular wellness.

Active substance: Atorvastatin
SKU: Atorlip 5 Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Atorlip 5 belongs to a class of medications known as HMG-CoA reductase inhibitors, commonly referred to as statins. It is formulated to lower elevated serum total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B, and triglycerides, while assisting in raising high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia or mixed dyslipidemia.

This medication is dispensed by prescription only in the United States, in accordance with federal and state pharmaceutical regulations. Effective lipid management with Atorlip 5 is typically integrated into a comprehensive therapeutic strategy that includes a low-fat diet, weight management, and regular physical activity to decrease overall cardiovascular risk.

Attribute Details
Active ingredient Atorvastatin calcium (5 mg)
Therapeutic class HMG-CoA reductase inhibitor (Statin)
Dosage form Oral tablet
Route of administration Oral
Primary purpose Lipid-lowering and cardiovascular risk reduction
Prescription status Prescription only (Rx)

Clinical Profile and Usage

Main uses

Atorlip 5 is indicated as an adjunct to dietary modifications for the reduction of elevated total cholesterol, LDL-C, apolipoprotein B, and triglyceride levels in adult patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia, and mixed dyslipidemia. A low starting strength such as 5 mg may be selected when subtle lipid adjustments are required, or when patient factors necessitate conservative dosing. Additionally, atorvastatin is indicated to reduce the risk of major cardiovascular events–such as non-fatal myocardial infarction, stroke, or revascularization procedures–in adults presenting with multiple cardiovascular risk factors including age, hypertension, low HDL-C, or smoking history.

How the drug works

The active compound, atorvastatin calcium, selectively and competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This hepatic enzyme catalyzes the conversion of HMG-CoA to mevalonate, representing the early rate-limiting step in endogenous cholesterol biosynthesis. By decreasing intracellular cholesterol concentrations in hepatocytes, atorvastatin induces an up-regulation of high-affinity LDL cell-surface receptors. This structural adaptation accelerates the clearance and catabolism of circulating LDL particles from the plasma, effectively diminishing circulating concentrations of LDL cholesterol and intermediate-density lipoproteins.

How it’s absorbed and eliminated

Following oral administration, atorvastatin is rapidly absorbed, attaining peak plasma concentrations (Cmax) within 1 to 2 hours. The absolute bioavailability of parent atorvastatin is approximately 14%, attributable to extensive presystemic clearance in gastrointestinal mucosa and hepatic first-pass metabolism. The drug is extensively metabolized by cytochrome P450 3A4 (CYP3A4) to active ortho- and parahydroxylated derivatives, which account for approximately 70% of the circulating HMG-CoA reductase inhibitory activity. While the mean plasma elimination half-life of parent atorvastatin is approximately 14 hours, the half-life of HMG-CoA reductase inhibition ranges from 20 to 30 hours due to active metabolites. Elimination occurs primarily via biliary excretion following hepatic processing, with less than 2% recovered in urine.

Dosing schedule

The dosing regimen of Atorlip 5 must be tailored individually according to baseline lipid parameters, therapeutic targets, and patient tolerability. The recommended dose is administered orally once daily, with or without food, at any time of day. Consistency in administration time supports adherence and uniform therapeutic exposure. The 5 mg dose may be utilized in patients requiring initial mild lipid reduction or in populations susceptible to statin toxicity due to renal insufficiency, advanced age, or concomitant drug therapy. Prescribers assess plasma lipid levels within 2 to 4 weeks of treatment initiation to determine whether dosage adjustments are warranted.

First days of treatment

During the initial phase of therapy with Atorlip 5, patients generally do not experience immediate perceptible physiological changes, as lipid-lowering agents do not yield immediate symptomatic effects. Pharmacodynamic activity begins promptly within the liver, leading to measurable reductions in plasma cholesterol levels within 1 to 2 weeks. Maximal therapeutic efficacy is typically observed within 4 weeks of consistent administration. It is vital for patients to maintain prescribed dietary regimens and daily medication routines regardless of the absence of overt physical sensations.

Safety, Precautions, and Interactions

Adverse reactions

Atorvastatin is generally well tolerated, though adverse clinical events may occur. Common side effects reported in clinical studies include nasopharyngitis, arthralgia, diarrhea, dyspepsia, urinary tract infection, and mild musculoskeletal discomfort. Laboratory abnormalities may include transient elevations in serum transaminases (ALT and AST). Statins infrequently induce myopathy, characterized by unexplained muscle pain, tenderness, or weakness associated with serum creatine kinase (CK) elevations exceeding ten times the upper limit of normal. Rhabdomyolysis–a rare but severe condition involving skeletal muscle necrosis and potential acute renal failure–represents a serious adverse effect requiring immediate intervention.

Important precautions

Atorlip 5 is contraindicated in patients with active liver disease, including unexplained persistent elevations of serum transaminases, and in individuals with hypersensitivity to atorvastatin or any inactive ingredients. Statins should be prescribed with caution in patients who consume substantial amounts of alcohol or have a history of hepatic disorders. Statin therapy is contraindicated during pregnancy and lactation, as cholesterol and its biosynthetic derivatives are essential for fetal development and infant growth. Elderly individuals (aged 65 years and older) should be monitored closely for muscular symptoms.

Compatibility with other medicines

Co-administration of Atorlip 5 with strong CYP3A4 inhibitors markedly increases systemic exposure to atorvastatin, elevating the risk of myopathy and rhabdomyolysis. Concomitant use with azole antifungals (such as itraconazole or ketoconazole), macrolide antibiotics (such as clarithromycin or erythromycin), HIV protease inhibitors, or cobicistat-containing regimens requires careful risk assessment or dosage modification. Concurrent administration with gemfibrozil, other fibrates, or lipid-altering doses of niacin increases the likelihood of muscle toxicity. If co-administration with cyclosporine or hepatitis C antiviral therapies is necessary, lower statin dosing or alternative therapy must be instituted.

Food and alcohol interactions

Consuming large quantities of grapefruit juice (exceeding 1.2 liters daily) during therapy with Atorlip 5 should be avoided. Grapefruit components inhibit intestinal CYP3A4, thereby elevating peak plasma concentrations and systemic AUC of atorvastatin. Modest intake of grapefruit juice poses less clinical risk, though avoidance remains a prudent standard. Regular or excessive consumption of alcohol should be restricted, as chronic alcohol use combined with statin therapy heightens the risk of liver injury and transaminase elevation.

If you skip a dose

If a dose of Atorlip 5 is omitted, it should be taken as soon as remembered on the same day. If more than 12 hours have elapsed since the regularly scheduled time, the missed dose should be skipped, and the standard schedule resumed the following day. Patients should not take two doses simultaneously to compensate for a missed tablet, as doubling the dose elevates the risk of adverse reactions without conferring therapeutic benefit.

Storage and expiration

Atorlip 5 tablets should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with short excursions permitted between 15°C and 30°C (59°F to 86°F). The medication must be kept in its original packaging to protect the contents from moisture, excessive heat, and direct light exposure. Store securely out of the reach of children and pets. Medication that has passed the expiration date printed on the container must be disposed of properly according to local guidelines.

Common Questions

Is Atorlip 5 taken in the morning or at night?

Atorlip 5 may be taken at any time of day, with or without food. Because atorvastatin and its active metabolites maintain an extended pharmacodynamic half-life of 20 to 30 hours, inhibition of hepatic cholesterol synthesis remains consistent regardless of whether the dose is administered in the morning or evening, provided daily timing remains consistent.

What should be done if muscle pain develops while taking this medication?

If unexplained muscle pain, tenderness, or weakness develops–particularly when accompanied by fever or general malaise–the patient should contact their healthcare provider promptly. Evaluation may include measuring serum creatine kinase levels to differentiate benign muscle discomfort from statin-induced myopathy.

Can grapefruit juice be consumed while taking Atorlip 5?

Large quantities of grapefruit juice (exceeding 1.2 liters per day) inhibit CYP3A4 metabolism, increasing systemic atorvastatin levels and muscular toxicity risks. Patients are advised to limit or avoid grapefruit intake to maintain predictable medication plasma concentrations.

How frequently are blood tests required during treatment?

Serum lipid levels and baseline hepatic transaminase values are evaluated prior to initiating therapy. Follow-up lipid panels are typically conducted 2 to 4 weeks after starting Atorlip 5 or adjusting the dose, and periodically every 3 to 12 months thereafter based on clinical stability and provider discretion.

Does Atorlip 5 interact with over-the-counter pain relievers?

Standard over-the-counter analgesics, such as acetaminophen or ibuprofen, do not share significant metabolic pathways with atorvastatin when used occasionally at therapeutic doses. Patients should consult a pharmacist or physician before introducing new chronic medications to verify individual safety.

In accordance with FDA regulatory guidelines for prescription lipid-lowering agents.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

5mg

Package

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία